News
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
The first trial of its kind saw one drug come out on top. Weight loss drugs have been pitted against each other in a first of ...
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...
Weight loss drugs and jabs have become more popular and a recent study looked at the effectiveness of two drugs ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results